Juniper Pharmaceuticals, Inc., a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring (IVR) technology. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. The company is also developing COL-1077, a lidocaine bioadhesive gel, which is in Phase 2b clinical trial for use as an acute use anesthetic for pain from minimally invasive gynecological procedures. Its products in preclinical development include JNP-0101, an oxybutynin IVR to treat overactive bladder in women; JNP-0201, a product candidate with natural progesterone and natural estradiol for used in hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone IVR used for the prevention of preterm birth. In addition, Juniper Pharmaceuticals, Inc. provides pharmaceutical development, clinical trial manufacturing, analytical, and consulting services. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.
http://www.priceseries.com/trade/JNP-Juniper-Pharmaceuticals-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2018010220180119.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments